Linezolid Sandoz (Linezolid)

Linezolid is indicated for the treatment of infections caused by susceptible Gram‑positive bacteria, particularly in the following clinical situations:

• Methicillin‑resistant Staphylococcus aureus (MRSA) infections: effective for skin, soft tissue and bloodstream infections caused by MRSA.
• Community‑acquired bacterial pneumonia: used to treat pneumonia caused by susceptible Streptococcus pneumoniae and other Gram‑positive pathogens.
• Skin and soft tissue infections: resolves cellulitis, abscesses and wound infections due to susceptible Gram‑positive organisms.
• Hospital‑acquired or ventilator‑associated pneumonia: provides coverage against resistant Gram‑positive pathogens when other options are limited.

• Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. This binding prevents formation of the initiation complex, thereby halting translation of essential proteins and leading to bacteriostatic activity against susceptible Gram‑positive organisms. The drug’s high affinity for the ribosomal RNA site distinguishes it from other protein synthesis inhibitors and contributes to its activity against strains resistant to other classes, such as β‑lactams and glycopeptides.

Linezolid may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: loose stools that may be self‑limiting.
• Headache: transient cranial discomfort.

Serious or Rare Side Effects

• Myelosuppression: significant decrease in blood cell production.
• Serotonin syndrome: risk when combined with serotonergic agents.
• Optic neuropathy: visual disturbances and potential vision loss.

When prescribing Linezolid, clinicians should consider several safety measures.

• Renal impairment: monitor kidney function and adjust therapy if needed.
• Hepatic dysfunction: assess liver enzymes before and during treatment.
• Hematologic monitoring: perform regular complete blood counts to detect thrombocytopenia or anemia.
• Concomitant serotonergic drugs: avoid or use with caution due to risk of serotonin syndrome.
• Store at ambient temperature: keep tablets below 25 °C in the original packaging, protected from moisture and direct sunlight.

Linezolid interacts with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid)

• Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic agents: may precipitate serotonin syndrome.
• Rifampicin: induces hepatic enzymes, markedly reducing linezolid plasma concentrations.

Moderate Interactions (Monitor Closely)

• MAO inhibitors: additive effect on monoamine levels, monitor for hypertensive reactions.
• Warfarin: may enhance anticoagulant effect, check INR regularly.
• Anticonvulsants (e.g., carbamazepine): may lower linezolid levels, adjust dosage if clinically indicated.